Life science leader executive editor blog Life science leader executive editor blog

The Wider Net — JPM Healthcare Conference 2017 In SF
The Wider Net — JPM Healthcare Conference 2017 In SF At the JPM conference, I spend the bulk of my time meeting with a string of companies, but as various as they are, they all share the common challenge of risk and uncertainty in the development of human therapeutics. For us in the press, it can be tempting to toss companies into easy categories such as size, stage of research, market cap  - but then, it’s fun and interesting to let the patterns among the companies emerge spontaneously ...  Continue Reading...
Night Of Light: California Life Science Association (CLSA)
Night Of Light: California Life Science Association (CLSA) Because I live only a day-trip away from San Francisco, it is convenient for me to travel there for industry events — a trek always accompanied by reflective reveries for the hometown of my film-student days. So, for the third time since June, and with another week scheduled for early January, I am once again city-bound, leaving home mid-day and getting into my hotel in plenty of time to make the 5:30 PM reception for the annual Pantheon...  Continue Reading...
BIO Shines In San Francisco
BIO Shines In San Francisco This year, the BIO Investor Forum (#BIF16) in San Francisco enjoyed its largest turnout ever, basked in the light and warmth of a dynamic industry that may not solve all of the world’s problems, but shines upon us, a salubrious star. Will the industry’s star shine upon everyone, or leave most of humanity in the shadows?  Continue Reading...
IO: Science Still Drives The Business
IO: Science Still Drives The Business How much science does a business person need to know? In this industry, the more the better. Without at least an excellent layperson’s understanding of the company’s scientific underpinnings, a life science executive will remain vulnerable to the greatest of all hazards in managing the business — today’s news.  Continue Reading...
Living With Pricing
Living With Pricing Life Science Leader Launches a Search for Common Ground  Continue Reading...
BIO Still Delivers
BIO Still Delivers If the BIO International Convention did nothing but assemble the 16,000 people who came to this year’s meeting in San Francisco, simply giving them a space to talk, that alone would be a great achievement.  Continue Reading...
An Absent Life Science Blogger’s Backstory
An Absent Life Science Blogger’s Backstory Alas, I am a specialized ignoramus, or dilettante; aka, a journalist. To ask even the most basic questions about the series topic — generally, new therapeutic approaches to neurodegenerative diseases — I first put myself through a veritable college course on the subject, reading and rereading through a tall (cyber) pile of related scientific, medical, and commercial literature. And yet, it is not the unseen labor I regret, but the...  Continue Reading...
Write Thinking — Biopharma At the Turn of the Year
Write Thinking — Biopharma At the Turn of the Year Writing is reinforced thinking. It is a stronger, more constructive way of moving through the thought world. Because I am a trade journalist covering the life science industry, all of those things tend to appear to me in industry terms. Take the drug-pricing debate, for example.     Continue Reading...
Startups & Outsourcing — Opposite Poles or Virtual Partners?
Startups & Outsourcing — Opposite Poles or Virtual Partners? Let’s face it, finding the money often captures all but a few crumbs of the typical startup CEO’s attention. Laser-sharp illustrations in the company’s dog-and-pony show may present its scientific platform with convincing clarity and purpose, but traditionally, investment conferences have not been a place where the dollar-hungry startup talks about the infrastructure it must build or hire to turn its science into a medical...  Continue Reading...
Reliving the Past, Shaping the Future of Cancer Therapy
Reliving the Past, Shaping the Future of Cancer Therapy A news item on AZ’s new “crowdsourcing” approach to cancer-drug treatment. The report uncritically hailed the program as a veritable revolution in cancer therapy that could yield greatly improved results from combinations of traditional chemotherapeutics and, presumably, other approved drugs with different modalities such as molecular-pathway targeting.  Continue Reading...

BE A CONTRIBUTOR